Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Recent translational research into targeted therapy for liposarcoma.

Patel RB, Li T, Liao Z, Jaldeepbhai JA, Perera HAPNV, Muthukuda SK, Dhirubhai DH, Singh V, Du X, Yang J.

Stem Cell Investig. 2017 Mar 15;4:21. doi: 10.21037/sci.2017.02.09. eCollection 2017. Review.

2.

Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer.

Xie S, Shen C, Tan M, Li M, Song X, Wang C.

Oncotarget. 2017 Apr 18;8(16):27216-27239. doi: 10.18632/oncotarget.16111.

3.

Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis.

Peng B, Shi R, Jiang W, Ding YH, Dong MQ, Zhu WG, Xu X.

Cell Biosci. 2017 Mar 23;7:15. doi: 10.1186/s13578-017-0142-x. eCollection 2017.

4.

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM.

Immunity. 2017 Feb 21;46(2):197-204. doi: 10.1016/j.immuni.2017.02.001.

PMID:
28228279
5.

Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.

Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, Chuman H, Morioka H, Matsumoto M, Nakamura M, Kubo T, Kato M, Kohno T, Kawai A, Kondo T, Ichikawa H.

Oncotarget. 2017 Feb 21;8(8):12941-12952. doi: 10.18632/oncotarget.14652.

6.

Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA.

BMC Cancer. 2017 Jan 6;17(1):29. doi: 10.1186/s12885-016-2992-8.

7.

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, Rosen G.

Clin Sarcoma Res. 2016 Dec 30;6:24. doi: 10.1186/s13569-016-0064-0. eCollection 2016.

8.

Modeling synovial sarcoma metastasis in the mouse: PI3'-lipid signaling and inflammation.

Barrott JJ, Kafchinski LA, Jin H, Potter JW, Kannan SD, Kennedy R, Mosbruger T, Wang WL, Tsai JW, Araujo DM, Liu T, Capecchi MR, Lazar AJ, Jones KB.

J Exp Med. 2016 Dec 12;213(13):2989-3005. Epub 2016 Nov 9.

PMID:
27956588
9.

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.

Kerr LT, Donoghue JF, Wilding AL, Johns TG.

Sarcoma. 2016;2016:3484673. Epub 2016 Oct 16.

10.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.

11.

XAB2 functions in mitotic cell cycle progression via transcriptional regulation of CENPE.

Hou S, Li N, Zhang Q, Li H, Wei X, Hao T, Li Y, Azam S, Liu C, Cheng W, Jin B, Liu Q, Li M, Lei H.

Cell Death Dis. 2016 Oct 13;7(10):e2409. doi: 10.1038/cddis.2016.313.

12.

Liposarcoma: Multimodality Management and Future Targeted Therapies.

Crago AM, Dickson MA.

Surg Oncol Clin N Am. 2016 Oct;25(4):761-73. doi: 10.1016/j.soc.2016.05.007. Epub 2016 Jul 30. Review.

PMID:
27591497
13.

Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.

Okada T, Lee AY, Qin LX, Agaram N, Mimae T, Shen Y, O'Connor R, López-Lago MA, Craig A, Miller ML, Agius P, Molinelli E, Socci ND, Crago AM, Shima F, Sander C, Singer S.

Cancer Discov. 2016 Oct;6(10):1148-1165. Epub 2016 Aug 30.

PMID:
27577794
14.

Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines.

Salawu A, Fernando M, Hughes D, Reed MW, Woll P, Greaves C, Day C, Alhajimohammed M, Sisley K.

Br J Cancer. 2016 Oct 25;115(9):1058-1068. doi: 10.1038/bjc.2016.259. Epub 2016 Aug 25.

PMID:
27560552
15.

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.

Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK.

Ann Oncol. 2016 Oct;27(10):1855-60. doi: 10.1093/annonc/mdw281. Epub 2016 Aug 8.

PMID:
27502708
16.

The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study.

Jour G, Wang L, Middha S, Zehir A, Chen W, Sadowska J, Healey J, Agaram NP, Choi L, Nafa K, Hameed M.

J Pathol Clin Res. 2015 Oct 29;2(1):9-20. doi: 10.1002/cjp2.29. eCollection 2016 Jan.

17.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR.

J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25.

18.

The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Yang J, Ren Z, Du X, Hao M, Zhou W.

Stem Cell Investig. 2014 Oct 27;1:18. doi: 10.3978/j.issn.2306-9759.2014.10.01. eCollection 2014. Review.

19.

Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N.

Lab Invest. 2016 Aug;96(8):885-94. doi: 10.1038/labinvest.2016.64. Epub 2016 Jun 6.

20.

Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis.

Gao L, Hong X, Guo X, Cao D, Gao X, DeLaney TF, Gong X, Chen R, Ni J, Yao Y, Wang R, Chen X, Tian P, Xing B.

Oncotarget. 2016 Jul 12;7(28):43557-43569. doi: 10.18632/oncotarget.9618.

Supplemental Content

Support Center